These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

257 related articles for article (PubMed ID: 10673654)

  • 1. Past administration of beta-lactam antibiotics and increase in the emergence of beta-lactamase-producing bacteria in patients with orofacial odontogenic infections.
    Kuriyama T; Nakagawa K; Karasawa T; Saiki Y; Yamamoto E; Nakamura S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Feb; 89(2):186-92. PubMed ID: 10673654
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Antimicrobial susceptibility of major pathogens of orofacial odontogenic infections to 11 beta-lactam antibiotics.
    Kuriyama T; Karasawa T; Nakagawa K; Nakamura S; Yamamoto E
    Oral Microbiol Immunol; 2002 Oct; 17(5):285-9. PubMed ID: 12354209
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bacteriologic features and antimicrobial susceptibility in isolates from orofacial odontogenic infections.
    Kuriyama T; Karasawa T; Nakagawa K; Saiki Y; Yamamoto E; Nakamura S
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2000 Nov; 90(5):600-8. PubMed ID: 11077383
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prevalence of extended spectrum beta-lactamase among multidrug resistant gram-negative isolates from a general hospital in Saudi Arabia.
    Kader AA; Kumar AK
    Saudi Med J; 2004 May; 25(5):570-4. PubMed ID: 15138522
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Incidence of beta-lactamase production and antimicrobial susceptibility of anaerobic gram-negative rods isolated from pus specimens of orofacial odontogenic infections.
    Kuriyama T; Karasawa T; Nakagawa K; Yamamoto E; Nakamura S
    Oral Microbiol Immunol; 2001 Feb; 16(1):10-5. PubMed ID: 11169133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dissemination of the metallo-beta-lactamase gene blaIMP-4 among gram-negative pathogens in a clinical setting in Australia.
    Peleg AY; Franklin C; Bell JM; Spelman DW
    Clin Infect Dis; 2005 Dec; 41(11):1549-56. PubMed ID: 16267725
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Resistance to newer beta-lactams and related ESBL types in gram-negative nosocomial isolates in Turkish hospitals: results of the multicentre HITIT study].
    Gür D; Gülay Z; Akan OA; Aktaş Z; Kayacan CB; Cakici O; Eraç B; Gültekin M; Oğünç D; Söyletir G; Unal N; Uysal S
    Mikrobiyol Bul; 2008 Oct; 42(4):537-44. PubMed ID: 19149074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ertapenem for the treatment of extended-spectrum beta-lactamase-producing Gram-negative bacterial infections.
    Teng CP; Chen HH; Chan J; Lye DC
    Int J Antimicrob Agents; 2007 Oct; 30(4):356-9. PubMed ID: 17631986
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Beta-lactamase production and the patterns of bacterial resistance, 1988-1991].
    Rodríguez Noriega E; Morfín Otero R; Esparza Ahumada S
    Gac Med Mex; 1994; 130(5):355-60. PubMed ID: 7607365
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
    Ciofu O
    APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
    [TBL] [Abstract][Full Text] [Related]  

  • 11. New β-lactam antibiotics and β-lactamase inhibitors.
    Bush K; Macielag MJ
    Expert Opin Ther Pat; 2010 Oct; 20(10):1277-93. PubMed ID: 20839927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Development of beta-lactam antibiotic resistance in gram-negative bacteria and the impact of resistance on therapy].
    Bedenić B
    Lijec Vjesn; 1999; 121(7-8):249-57. PubMed ID: 10573961
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The emergence and implications of metallo-beta-lactamases in Gram-negative bacteria.
    Walsh TR
    Clin Microbiol Infect; 2005 Nov; 11 Suppl 6():2-9. PubMed ID: 16209700
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Increasing extended-spectrum beta-lactamase production and quinolone resistance among Gram-negative bacilli causing intra-abdominal infections in the Asia/Pacific region: data from the Smart Study 2002-2006.
    Ko WC; Hsueh PR
    J Infect; 2009 Aug; 59(2):95-103. PubMed ID: 19564044
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Broad-spectrum beta-lactamases in Gram-negative bacteria].
    Sundsfjord A; Simonsen GS; Haldorsen B; Lundblad EW; Samuelsen O
    Tidsskr Nor Laegeforen; 2008 Dec; 128(23):2741-5. PubMed ID: 19079424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanisms of resistance to beta-lactams in some common Gram-negative bacteria causing nosocomial infections.
    Suárez CJ; Lolans K; Villegas MV; Quinn JP
    Expert Rev Anti Infect Ther; 2005 Dec; 3(6):915-22. PubMed ID: 16307504
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Parenteral carbapenems.
    Shah PM
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():175-80. PubMed ID: 18154543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sulbactam-containing beta-lactamase inhibitor combinations.
    Akova M
    Clin Microbiol Infect; 2008 Jan; 14 Suppl 1():185-8. PubMed ID: 18154545
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Clinically important beta-lactamases of gram-negative bacteria: extended-spectrum beta-lactamases (ESBL)].
    Hrabák J
    Epidemiol Mikrobiol Imunol; 2007 Aug; 56(3):103-11. PubMed ID: 17900058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Emergence of extended spectrum beta lactamase mediated resistance in neonatal septicemia.
    Vinodkumar CS; Neelagund YF
    Indian J Pathol Microbiol; 2006 Oct; 49(4):616-9. PubMed ID: 17183878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.